Evogene's Biomica Completes Phase I Enrollment for Cancer Drug BMC128
Ticker: EVGN · Form: 6-K · Filed: Jan 17, 2024 · CIK: 1574565
Complexity: simple
Sentiment: bullish
Topics: biotechnology, clinical-trial, drug-development, subsidiary-update
TL;DR
**Evogene's subsidiary just hit a key milestone for its cancer drug trial!**
AI Summary
Evogene Ltd.'s subsidiary, Biomica Ltd., announced on January 17, 2024, that it successfully completed Phase I trial enrollment for its microbiome-based immuno-oncology drug, BMC128. This trial is evaluating the safety and tolerability of BMC128, a crucial step in its development. This matters to investors because successful completion of this phase could de-risk the drug and potentially increase its future value, signaling progress in Evogene's biotechnology pipeline.
Why It Matters
This milestone indicates progress in the development of a potential new cancer treatment, which could significantly impact Evogene's future revenue and market position if successful.
Risk Assessment
Risk Level: medium — While completing Phase I enrollment is positive, the drug still needs to demonstrate safety and efficacy in subsequent, more extensive trials, which carry significant risk.
Analyst Insight
A smart investor would monitor Biomica's upcoming announcements regarding the Phase I trial results for BMC128, as positive data could signal further upside for Evogene's stock.
Key Players & Entities
- Evogene Ltd. (company) — parent company
- Biomica Ltd. (company) — subsidiary developing the drug
- Yaron Eldad (person) — Chief Financial Officer of Evogene Ltd.
- BMC128 (other) — microbiome-based immuno-oncology drug
- January 17, 2024 (date) — date of announcement and filing
Forward-Looking Statements
- Biomica will release initial safety and tolerability data from the Phase I trial of BMC128. (Biomica Ltd.) — medium confidence, target: Q3 2024
- Evogene's stock price will see a moderate increase if Phase I results for BMC128 are positive. (Evogene Ltd.) — medium confidence, target: Q4 2024
FAQ
What is the name of the drug that Biomica Ltd. is developing?
Biomica Ltd. is developing a microbiome-based immuno-oncology drug named BMC128, as stated in the press release attached as Exhibit 99.1.
What was the purpose of the Phase I trial for BMC128?
The Phase I trial for BMC128 was designed to evaluate the safety and tolerability of the drug, according to the Exhibit 99.1 press release.
When did Evogene Ltd. announce the completion of Phase I trial enrollment for BMC128?
Evogene Ltd. announced the successful completion of Phase I trial enrollment for BMC128 on January 17, 2024, as detailed in the filing.
Who signed the 6-K report on behalf of Evogene Ltd.?
The 6-K report was signed by Yaron Eldad, Chief Financial Officer of Evogene Ltd., on January 17, 2024.
What type of company is Biomica Ltd. described as in the filing?
Biomica Ltd. is described as a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics in Exhibit 99.1.
Filing Stats: 199 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-01-17 07:00:06
Filing Documents
- zk2430788.htm (6-K) — 10KB
- exhibit_99-1.htm (EX-99.1) — 12KB
- image00001.jpg (GRAPHIC) — 5KB
- 0001178913-24-000179.txt ( ) — 31KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On January 17, 2024, Evogene Ltd., or Evogene, announced that its subsidiary, Biomica Ltd., or Biomica, reported that it successfully completed Phase I trial enrollment for microbiome-based immuno-oncology drug. A copy of the press release is attached hereto as Exhibit 99. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 17, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug.